Treatment of noninvasive carcinoma: Fifteen-Year results at the National Cancer Center Hospital in Tokyo

Breast Cancer ◽  
2000 ◽  
Vol 7 (4) ◽  
pp. 341-344 ◽  
Author(s):  
Sadako Akashi-Tanaka ◽  
Takashi Fukutomi ◽  
Takeshi Nanasawa ◽  
Kaneyuki Matsuo ◽  
Tadashi Hasegawa ◽  
...  
Keyword(s):  
National Cancer Center Hospital ◽  
Cancer Center ◽  
Center Hospital ◽  
Noninvasive Carcinoma

scholarly journals Autopsy of bone tumors at National Cancer Center Hospital

1964 ◽  
Vol 14 (1) ◽  
pp. 43-45
Author(s):  
I. Maeyama ◽  
S. Sato ◽  
S. Goto
Keyword(s):  
Bone Tumors ◽  
National Cancer Center Hospital ◽  
Cancer Center ◽  
Center Hospital

Safety and Evidence of Off-Label Use of Approved Drugs at the National Cancer Center Hospital in Japan

2020 ◽  
pp. OP.20.00131
Author(s):  
Seiko Bun ◽  
Kan Yonemori ◽  
Hiroko Sunadoi ◽  
Rena Nishigaki ◽  
Emi Noguchi ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Pharmaceutical Products ◽  
National Cancer Center Hospital ◽  
Phase Iii ◽  
Cancer Center ◽  
Off Label Use ◽  
Pharmaceutical Development ◽  
Off Label ◽  
Center Hospital ◽  
Label Use

PURPOSE: In Japan, for pharmaceutical products to be covered by public medical insurance, their efficacy and safety must first be confirmed in clinical trials. To our knowledge, this study is the first investigation into the off-label use of pharmaceutical products at a high-volume cancer treatment center in Japan. The objective of this study is to explore the framework necessary for future pharmaceutical development and regulatory approval in the field of oncology by surveying the frequency of and indications for off-label use of pharmaceutical products at the National Cancer Center Hospital in Tokyo, Japan. MATERIALS AND METHODS: The pharmaceutical products used off-label in daily practice from 2003 to 2015 at the National Cancer Center Hospital were retrospectively examined based on applications that had been submitted to an internal review committee requesting off-label use. RESULTS: A total of 1,390 applications were submitted during the study period. The most frequently used supporting documents were the results of phase II trials, followed by case series and phase III trials. The cancer most frequently treated with off-label drugs was sarcoma (15.1%), followed by urologic cancer (9.2%) and GI cancer (7.6%). CONCLUSION: As reported in previous studies, pharmaceutical products were generally used off-label for the treatment of rare cancers, for which large-scale clinical trials are difficult to conduct. Continued discussion of the types of frameworks that are needed to guide pharmaceutical development is necessary.

Sign in / Sign up

Export Citation Format

Share Document